Personalis to Participate in Upcoming Investor Conferences

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the following upcoming investor conferences.

• H.C. Wainwright 22nd Annual Global Investment Conference
  Presenting on Wednesday, September 16 at 11 a.m. Eastern Time

• Morgan Stanley 18th Annual Global Healthcare Conference
  Fireside chat on Thursday, September 17 at 3:30 p.m. Eastern Time

• Cowen's Liquid Biopsy Summit
  Presenting on Thursday, September 24 at 2:30 p.m. Eastern Time

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence two million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).